These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 8903661)

  • 101. Effects of lacidipine on the carotid and cerebral circulations in essential hypertension.
    Safar ME
    J Cardiovasc Pharmacol; 1991; 17 Suppl 4():S51-4. PubMed ID: 1726008
    [TBL] [Abstract][Full Text] [Related]  

  • 102. Calcium antagonism: aldosterone and vascular responses to catecholamines and angiotensin II in man.
    Elliott HL
    J Hypertens Suppl; 1993 Dec; 11(6):S13-6. PubMed ID: 8169376
    [TBL] [Abstract][Full Text] [Related]  

  • 103. Calcium antagonists as a new treatment modality in hypertension.
    Laragh JH
    Angiology; 1988 Jan; 39(1 Pt 2):100-5. PubMed ID: 3277491
    [TBL] [Abstract][Full Text] [Related]  

  • 104. Resistance and conduit arteries following converting enzyme inhibition in hypertension.
    Safar ME; van Bortel LM; Struijker-Boudier HA
    J Vasc Res; 1997; 34(2):67-81. PubMed ID: 9167639
    [TBL] [Abstract][Full Text] [Related]  

  • 105. Arterial structural modifications in hypertension. Effects of treatment.
    Thom S
    Eur Heart J; 1997 Nov; 18 Suppl E():E2-4. PubMed ID: 9402464
    [TBL] [Abstract][Full Text] [Related]  

  • 106. The central nervous system and effective antihypertensive effects of a calcium channel blocker.
    Takahashi H; Yoshimura M
    J Cardiovasc Pharmacol; 1987; 10 Suppl 10():S129-33. PubMed ID: 2455113
    [TBL] [Abstract][Full Text] [Related]  

  • 107. Calcium antagonists in hypertensive disease: experimental evidence for a new therapeutic concept.
    Kazda S; Garthoff B; Luckhaus G
    Postgrad Med J; 1983; 59 Suppl 2():78-83. PubMed ID: 6351044
    [TBL] [Abstract][Full Text] [Related]  

  • 108. Clinical aspects of parathyroid hypertensive factor.
    Lewanczuk RZ; Benishin CG; Shan J; Pang PK
    J Cardiovasc Pharmacol; 1994; 23 Suppl 2():S23-6. PubMed ID: 7518541
    [TBL] [Abstract][Full Text] [Related]  

  • 109. [Clinical study of arterial rigidity. Part II. Remodeling of vessels in arterial hypertension and metabolic syndrome. possibilities of correction with drugs].
    Oleĭnikov VE; Matrosova IB
    Kardiologiia; 2009; 49(12):51-7. PubMed ID: 20038283
    [TBL] [Abstract][Full Text] [Related]  

  • 110. The L-arginine-nitric oxide pathway in hypertension.
    Kelm M
    Curr Hypertens Rep; 2003 Feb; 5(1):80-6. PubMed ID: 12530940
    [TBL] [Abstract][Full Text] [Related]  

  • 111. Can antihypertensive treatment reverse large-artery stiffening?
    Safar ME
    Curr Hypertens Rep; 2010 Feb; 12(1):47-51. PubMed ID: 20425158
    [TBL] [Abstract][Full Text] [Related]  

  • 112. Arterial structure in hypertension and the effects of angiotensin converting enzyme inhibition.
    Safar ME; Levy BI; London GM
    J Hypertens Suppl; 1992 Jul; 10(5):S51-7. PubMed ID: 1403234
    [TBL] [Abstract][Full Text] [Related]  

  • 113. Vascular remodeling and antihypertensive therapy: the example of cicletanine.
    Chabrier PE; Esanu A; Braquet P
    J Cardiovasc Pharmacol; 1993; 21 Suppl 1():S50-3. PubMed ID: 7681131
    [TBL] [Abstract][Full Text] [Related]  

  • 114. Coadministration of calcium antagonists and ACE inhibitors--is a skeptic convinced?: a personal view.
    Campbell RW
    Cardiovasc Drugs Ther; 1995 Aug; 9 Suppl 3():525-8. PubMed ID: 8562469
    [TBL] [Abstract][Full Text] [Related]  

  • 115. Targeting small arteries of hypertensive status with novel ATP-sensitive potassium channel openers.
    Wang H; Zhang YL; Chen YP
    Curr Vasc Pharmacol; 2005 Apr; 3(2):119-24. PubMed ID: 15853631
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]     [New Search]
    of 6.